美股市场个股详情
CTXR Citius Pharmaceuticals
- 0.6300
- -0.0576-8.38%
交易中 05/15 15:40 (美东)
1.14亿总市值-2739市盈率TTM
0.6775最高价0.6300最低价176.56万股成交量0.6750今开0.6876昨收114.72万成交额1.05%换手率亏损市盈率(静)1.81亿总股本1.400052周最高1.44市净率1.06亿流通值0.600052周最低--股息TTM1.68亿流通股30.0000历史最高--股息率TTM6.91%振幅0.4000历史最低0.6490平均价1股每手
Citius Pharmaceuticals股票讨论区
登录发表评论
$美国联合医疗(UTHR.US$ Phase 3
$Ironwood医药(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood医药(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$阿斯利康(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
7
1
1
$Citius Pharmaceuticals(CTXR.US$ Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
1
8
$Citius Pharmaceuticals(CTXR.US$ There's a couple desperate ppl for this stock the way they sent that alert all day.lol they probably stuck with a bunch of it at a stupid price.
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$和黄医药(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$和黄医药(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
$Citius Pharmaceuticals(CTXR.US$ Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma 4 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE
$Citius Pharmaceuticals(CTXR.US$ Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission! This is a resubmit from the CRL received from the FDA in JULY 2023! Thinking this time shou...
4
$Citius Pharmaceuticals(CTXR.US$ Citius Pharmaceuticals Completes Enrollment in Phase 3 Trial for Mino-Lok
MT Newswires· 2 mins ago![]()
MT Newswires· 2 mins ago
1
1
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Jimmy1819 : have you been investing professionally or as a hobby?